Patent · US Active

Prodrugs of nucleoside phosphonates

US11040047B2 · kind B2 · utility

0Cited by

0References

12Claims

0Family size

Assignee

Katholieke Universiteit Leuven · BE

Inventors

Graciela Andrei · Leuven, BE
Steven De Jonghe · Brussels, BE
Elisabetta Groaz · Leuven, BE
Piet Herdewijn · Wezemaal, BE
Min Luo · Leuven, BE
Dominique Schols · Herent, BE
Robert Snoeck · Woluwe-Saint-Lambert - Sint-Lambrechts-Woluwe, BE

Key dates

Filing date	Mar 21, 2018
Grant date	Jun 22, 2021
Priority date	—
Expiry date	Mar 21, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel phosphonoamidate prodrugs. The invention also relates to the use of these novel phosphonate-modified nucleosides to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses such as the herpes simplex virus 1, herpes simplex virus 2, human cytomegalovirus, varicella zoster virus, vaccinia virus and adenovirus.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.